SITC 2026 has ended. This guide stays up as the record of who was there. Next: SITC 2027, Nov 3–7, 2027 in National Harbor

Cell therapy at SITC 2026

Nov 4–8, 2026 Phoenix, AZ ~6k attendees Website

186 organizations at SITC 2026 present work in cell therapy, led by universities and research institutes. Between them they bring 660 presentations to the program. Most represented: MD Anderson Cancer Center, Mayo Clinic and University of Pittsburgh. As of Nov 2, 2026.

All 661 organizations at SITC 2026 →

Format
Top represented
Showing 1–1 of 186 organizations
OrganizationSITC 2026 Attendance
Cancer centres & hospitals
University of Texas comprehensive cancer center in Houston focused on cancer patient care, research and education.
Session
Thu Nov 5
12:00pm–1:30pm
Workshop
Thu Nov 5
7:00pm–8:00pm
Early Career Scientist Speed Mentoring
  1. 7:00pm–8:00pmSpeed Mentoring - Group Mentoring
  2. 7:00pm–7:30pmSpeed Mentoring - One-on-One
  3. 7:30pm–8:00pmSpeed Mentoring - One-on-One 2
Poster
Fri Nov 6
12:15–1:45pm
5:30–7pm
Poster
Sat Nov 7
12–1:30pm
6:40–8:10pm
Poster
Sat Nov 7
12–1:30pm
6:40–8:10pm
Session
Sat Nov 7
3:30pm–4:50pm
Oral Abstract Session 3
  1. 3:33pm–3:48pmClinical and translational evaluation of lifileucel in patients with metastatic undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma.Memorial Sloan Kettering Cancer Center
  2. 3:48pm–4:03pm3-Year landmark overall survival and quality-adjusted overall survival with RP1 combined with nivolumab in anti–PD-1–failed melanoma: Results from the IGNYTE trialUSC Norris Comprehensive Cancer Center
  3. 4:03pm–4:18pmThe SPEARHEAD-1 Trial of Afamitresgene autoleucel (Afami-cel) in Advanced Synovial Sarcoma: Factors Associated with Clinical OutcomesMemorial Sloan Kettering Cancer Center
  4. 4:18pm–4:33pmInitial clinical results from START-002: A Phase 1b/2 study of invikafusp alfa, a first-in-class dual T-cell agonist, in combination with sacituzumab govitecan in triple-negative or HR+/HER2- mBCMass General Brigham Cancer Institute
  5. 4:33pm–4:48pmMDNA11 Demonstrates Clinical Activity as Monotherapy and in Combination with Pembrolizumab in Biomarker-Enriched Gastrointestinal Malignancies, Including ICI-Refractory DiseaseNational Cancer Institute Pascale

Explore the full SITC 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Phoenix. Leave your work email and we’ll be in touch.

Privacy

Download the full SITC 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Find buyers in cell therapy

Tell us what you sell and we’ll find the people at organizations working on cell therapy most likely to buy it.

  • Who to contact
  • Their contact info
  • What to say
  • Free, no sign-up

Browse SITC 2026 by

Exhibit hall

Not affiliated with or endorsed by the Society for Immunotherapy of Cancer (SITC). Submit a correction